###begin article-title 0
Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population
###end article-title 0
###begin p 1
Conceived and designed the experiments: MM US PMK CF. Performed the experiments: MM EB CL FL EC CF FE DG. Analyzed the data: MM KTT AS MPF. Contributed reagents/materials/analysis tools: MG SD BN ML LMEG FMB DG ES MPA CC. Wrote the paper: MM PMK CF.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Albeit several studies pointed out the pivotal role that CD4+T cells have in Multiple Sclerosis, the CD8+ T cells involvement in the pathology is still in its early phases of investigation. Proteasome degradation is the key step in the production of MHC class I-restricted epitopes and therefore its activity could be an important element in the activation and regulation of autoreactive CD8+ T cells in Multiple Sclerosis.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 555 563 548 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 634 641 627 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
Immunoproteasomes and PA28-alphabeta regulator are present in MS affected brain area and accumulated in plaques. They are expressed in cell types supposed to be involved in MS development such as neurons, endothelial cells, oligodendrocytes, macrophages/macroglia and lymphocytes. Furthermore, in a genetic study on 1262 Italian MS cases and 845 controls we observed that HLA-A*02+ female subjects carrying the immunoproteasome LMP2 codon 60HH variant have a reduced risk to develop MS. Accordingly, immunoproteasomes carrying the LMP2 60H allele produce in vitro a lower amount of the HLA-A*0201 restricted immunodominant epitope MBP111-119.
###end p 5
###begin title 6
Conclusion/Significance
###end title 6
###begin p 7
The immunoproteasome LMP2 60HH variant reduces the risk to develop MS amongst Italian HLA-A*02+ females. We propose that such an effect is mediated by the altered proteasome-dependent production of a specific MBP epitope presented on the MHC class I. Our observations thereby support the hypothesis of an involvement of immunoproteasome in the MS pathogenesis.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 373 377 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g.</italic>
###xml 789 792 789 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Friese1">[1]</xref>
###xml 794 797 794 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Giovannoni1">[2]</xref>
###xml 799 802 799 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Fugger1">[3]</xref>
###xml 1075 1078 1075 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Friese2">[4]</xref>
###xml 654 659 <span type="species:ncbi:10090">mouse</span>
Multiple Sclerosis (MS) is the most common autoimmune disorder of the central nervous system (CNS). It is characterized by multifocal areas of demyelization (plaques), chronic inflammation and damage to oligodendrocytes and neurons. The cause of MS is still unknown and disease pathways are poorly understood. However, the association of HLA-DRB1*15 and other HLA class I (e.g. HLA-A*02 and HLA-A*03) and class II alleles, the presence of autoreactive T lymphocytes together with other inflammatory cells and cytokines in active MS lesions suggest an autoimmune pathogenesis. Accordingly, the experimental autoimmune encephalomyelitis (EAE), a classical mouse model for MS, can be induced by the administration of myelin antigens or CD4+ and CD8+ T lymphocytes specific for those antigens [1], [2], [3]. On the basis of recent results on EAE, it has been proposed that the first bout of the disease is mediated by CD8+ T cells while the first relapse and further disease are mediated by CD4+ T cells through different mechanisms such as antigen release and epitope spreading [4].
###end p 9
###begin p 10
###xml 281 284 281 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Kloetzel1">[5]</xref>
###xml 356 359 356 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-DiazHernandez1">[6]</xref>
###xml 361 364 361 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto1">[7]</xref>
###xml 650 653 638 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Kloetzel1">[5]</xref>
###xml 973 976 943 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Kloetzel1">[5]</xref>
###xml 978 981 948 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto2">[8]</xref>
###xml 1204 1207 1174 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Kramer1">[9]</xref>
###xml 1209 1213 1179 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Maksymowych1">[10]</xref>
###xml 1215 1219 1185 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-VargasAlarcon1">[11]</xref>
###xml 1514 1518 1480 1484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto3">[12]</xref>
###xml 1630 1633 1596 1599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto1">[7]</xref>
###xml 1596 1604 <span type="species:ncbi:9606">patients</span>
The antigen bound on Major Histocompatibility Complex class I (MHC-I) and presented to the T cell receptor (TCR) of CD8+ T cells, is normally produced by proteasomes. One of the proteasome isoforms, known as immunoproteasome, enhances the generation of specific antigenic epitopes [5] and its role in neurodegenerative diseases has recently been described [6], [7]. Immunoproteasome differs from the constitutive proteasome by the beta subunits with catalytic activity [beta1, beta2, beta5 into constitutive proteasome and Low Molecular Mass Polypeptide 2 (LMP2), Multicatalytic Endopeptidase Complex Subunit (MECL-1) and LMP7 into immunoproteasome] [5]. Immunoproteasome assembly can be induced by IFN-gamma, which also stimulates the expression of proteasome activator-alphabeta (PA28-alphabeta). This regulatory complex binds to the end of the 20S proteasome core, increasing the cleavage rate in an ATP-independent manner and affecting the quality of protein digestion [5], [8]. Moreover, a role for immunoproteasomes has been suggested in some autoimmune diseases such as ankylosing spondylitis and psoriasis because of the association of a polymorphism of its LMP2 subunit to the those pathologies [9], [10], [11]. This particular polymorphism is a non-conservative nucleotide base pair change at amino acid position 60 (in exon 3), resulting in two alleles, arginine (R) or histidine (H). It modifies the susceptibility of peripheral blood mononuclear cells to TNF-alpha induced-apoptosis in elderly donors [12], as well as the proteasome activity in brain protein extracts from Alzheimer patients and non-demented elderly [7].
###end p 10
###begin p 11
###xml 419 426 412 419 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 455 459 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Jurewicz1">[13]</xref>
###xml 461 465 454 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Tsuchida1">[14]</xref>
###xml 467 471 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Zang1">[15]</xref>
###xml 484 492 477 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
In this study, we investigated the presence of immunoproteasome in the CNS of MS patients and whether its LMP2 polymorphism might be involved in MS onset. The data we obtained indicates that immunoproteasomes and PA28-alphabeta regulator are present in MS CNS and that the LMP2 60HH genotype impinges upon MS, likely in part by reducing the production of a specific HLA-A*02 restricted Myelin Basic Protein epitope (MBP111-119) implicated in MS pathology [13], [14], [15] as shown in in vitro assays and in the presence of PA28-alphabeta. Furthermore, these results add further evidences on the complex role of HLA-A*02 allele in the pathogenesis of this disease.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin p 13
###xml 197 209 <span type="species:ncbi:9606">participants</span>
The Ethics Committees of the University of Bologna, Florence, Empoli, Milan and Eastern Piedmont approved this study. An informed written consent to participate in this study was obtained from all participants.
###end p 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and Controls
###end title 14
###begin p 15
###xml 887 891 887 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-McDonald1">[16]</xref>
###xml 1116 1120 1114 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto3">[12]</xref>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
###xml 802 810 <span type="species:ncbi:9606">patients</span>
###xml 1083 1091 <span type="species:ncbi:9606">patients</span>
Two independent MS populations were genotyped and compared to a common Italian control population. The samples consisted of: i. 694 MS patients (mean age: 38.8+/-11.7 years) for the first MS population consecutively referred to the Department of Neurology of the University of Florence, the Hospital of Empoli, the University of Eastern Piedmont (Novara); ii. 568 MS patients (mean age: 43.4+/-12.4 years) for the second MS population referred to the Institute of Experimental Neurology and Department of Neurology - San Raffaele Scientific Institute (Milan) and the IRCCS Fondazione Ospedale Maggiore Policlinico (Milan). The two independent samples were compared to a population of 845 age- and area-matched controls (mean age: 37.8+/-12.9 years) and then grouped providing a total MS sample of 1262 patients (mean age: 41.6+/-12.3). Inclusion criteria were a definite diagnosis of MS [16], age >/=18 years and written informed consent. All controls were carefully assessed to exclude diagnosis of inflammatory disorders. DNA was extracted from peripheral blood of controls and MS patients as previously described [12].
###end p 15
###begin title 16
Materials and Chemicals
###end title 16
###begin p 17
###xml 145 152 145 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;109</sub>
###xml 265 274 265 274 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLSRFSWGA</bold>
###xml 345 353 345 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119,</sub>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Jurewicz1">[13]</xref>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Tsuchida1">[14]</xref>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Zang1">[15]</xref>
###xml 481 486 481 486 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">26&#8211;35</sub>
###xml 514 521 514 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 571 575 571 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Valmori1">[17]</xref>
###xml 6 10 <span type="species:ncbi:9913">calf</span>
###xml 174 179 <span type="species:ncbi:9606">human</span>
###xml 392 399 <span type="species:ncbi:9606">patient</span>
Fetal calf serum and RPMI 1640 medium were from Biowhittaker (Belgium). The restriction enzymes were from MBI Fermentas (Latvia). The peptide MBP102-109 (seq. 102-129 of the human classical Myelin Basic Protein (MBP) isoform 5) has the following sequence: PSQGKGRGLSLSRFSWGAEGQRPGFGYG-CONH2 term. In bold the sequence of the analyzed epitope MBP111-119, HLA-A*0201 restricted, detected in MS patient blood and believed to be involved in MS [13], [14], [15]. The epitope (ELA)-MART126-35 used in comparison with MBP111-119 has the following sequence: ELAGIGILTV-COOH term [17]. All peptides have been synthesized by Dr. P. Henklein (Institute of Biochemistry, Medical Faculty Charite, Berlin, Germany).
###end p 17
###begin title 18
Immunohistochemistry (IHC)
###end title 18
###begin p 19
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Klare1">[18]</xref>
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Kloss1">[19]</xref>
###xml 567 575 567 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g001">Figure 1</xref>
###xml 577 578 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g002">2</xref>
###xml 583 584 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g003">3</xref>
###xml 1469 1473 1469 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Frischer1">[20]</xref>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 1950 1958 <span type="species:ncbi:9606">patients</span>
In the present study we described "immunoproteasomes" as any iso-form of proteasome that contains immunosubunits, thereby also including intermediate-types [18], [19]. IHC assays were performed on parietal lobes and rostral medulla (with MS plaques) of three MS patients (2 males, 37 and 49 years old; 1 female, 49 years old) and two young controls (females, 21 and 42 years old), provided by the Department of Hematology and Oncology, "L. and A. Seragnoli" Section of Anatomic Pathology, University of Bologna at Bellaria Hospital, Bologna, Italy. The IHC showed in Figure 1, 2 and 3 referred to autopsy samples derived from MS and control donors (respectively 49 and 42 years old) died by lung embolus and gastric hemorrhage, respectively. Both autopsies were carried out after 24 h from the death and almost all brain was included for histological examination and diagnostic definition of the disease. For the present study we selected brain areas carrying the histopathological features of active chronic plaques. These plaques, included for our immunohistochemical examination, were characterized by area of myelin reduction containing numerous macrophages with clear and foamy cytoplasm, positive with acid periodic Schiff staining (PAS) after diastase digestion. The same macrophages contained myelin degradation products, which reacted with the Luxol Fast Blue (LFB) staining and were mainly located in the peripheral part of the plaque as previously described [20]. The presence of macrophages and microglial cells has been evidenced by anti-CD68 immunostaining. In addition small venules, surrounded by mature lymphocytes, were present within the plaques. The lymphocyte population, characterized at the time of the diagnosis, consisted mainly of mature T cells, CD8 positive. The other MS and controls samples were biopsies obtained during surgery to investigate the presence of possible cancers. In the brain of subjects classified as MS patients characteristic MS lesions, were identified, instead of cancer markers; in contrast, neither cancer nor MS plaques were observed in the control sample.
###end p 19
###begin title 20
LMP2 subunit and PA28-alphabeta are expressed in CNS cortex and white matter of MS but not of young controls.
###end title 20
###begin p 21
###xml 578 585 <span type="species:ncbi:9606">patient</span>
Example of cortex (A, C) and plaque into white matter (B, D) of MS parietal lobe, stained with anti-LMP2 (A, B) and anti-PA28-alpha (C, D) Abs are shown. Different cell types, positive to the staining, are marked as following: 1. neurons; 2. luminal endothelial cells; 3. astrocytes; 4. oligodendrocytes (putative). Example of a parietal lobe cortex (E, G) and white matter (F, H) of young control stained with anti-LMP2 (E, F) and anti-PA28-alpha (G, H) Abs, which bind only luminal endothelial cells (see arrow). In (I) and (L) example of a parietal lobe white matter of a MS patient stained with anti-beta1 and anti-alpha4 Abs are shown, respectively. As expected, all cells are positive to both stainings. The representative samples here reported derived from gender- and age-matched MS and control samples. A, C, D, F, G, H, I scale bars = 50 microm; B, E, L scale bars = 25 microm.
###end p 21
###begin title 22
LMP2 subunit is accumulated in MS plaques.
###end title 22
###begin p 23
(A) Cortex, white matter and plaque of MS parietal lobe stained with anti-LMP2 Ab; an increase of cells expressing LMP2 in the plaque emerges. (B) In control parietal lobe, cortex and white matter marked with anti-LMP2 Ab show a detectable staining only in luminal endothelial cells. The labeling with anti-beta1 Ab of the same MS (C) and control (D) brain area do not show any difference neither between MS and control nor between grey and white matters. (E) Rostral medulla, with MS plaque into inferior olivar nucleus (arrow), stained with anti-LMP2 Ab, which mainly binds the MS plaque. The representative samples here reported derived from gender- and age-matched MS and control samples. A-D scale bars = 300 microm; E scale bar = 3 mm.
###end p 23
###begin title 24
LMP2 subunit and PA28-alphabeta are expressed in different cell types, including oligodendrocytes, macrophages and microglial cells in MS brains.
###end title 24
###begin p 25
A) To discriminate among oligodendrocytes and lymphocytes, we performed a double staining with anti-LMP2 (brown) and anti- CD45RB (red) Abs in parietal lobe of MS brains. Many oligodendrocytes (only brown stained; marked with 1) and lymphocytes (brown and red stained; marked with 2) are visible. B) Oligodendrocyte identification was confirmed by staining the same area with anti-LMP2 (brown) and anti-Olig2 (blue) Abs and observing a clear labeling of oligodendrocytes for both Olig2 and LMP2 (marked by arrow). C) Oligodendrocytes (marked by arrow) express also PA28-alphabeta as emerged by the double staining of MS parietal lobe with anti-PA28-alpha (blue) and anti-Olig2 (brown). A double staining for LMP2 (brown) and CD68 (red) verified that microglia/macrophages (marked with arrows) express the immunoproteasome subunit in parenchyma (D) and perivascular (E) parietal lobe of MS brains. F) Microglia/macrophages (marked with arrows) also express PA28-alphabeta as revealed by the double staining with anti-PA28-alpha (blue) and anti-CD68 (brown) Abs. A, E scale bars = 25 microm; B, C scale bars = 10 microm. D, F scale bars = 50 microm.
###end p 25
###begin p 26
###xml 53 56 53 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto1">[7]</xref>
###xml 1118 1122 1110 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Karadottir1">[21]</xref>
###xml 199 204 <span type="species:ncbi:10090">mouse</span>
###xml 222 227 <span type="species:ncbi:9606">human</span>
###xml 336 342 <span type="species:ncbi:9986">rabbit</span>
###xml 1064 1070 <span type="species:ncbi:9986">rabbit</span>
###xml 1336 1340 <span type="species:ncbi:9925">goat</span>
###xml 1625 1631 <span type="species:ncbi:9986">Rabbit</span>
###xml 1632 1637 <span type="species:ncbi:10090">Mouse</span>
Immunostaining was performed as previously described [7] adopting a dilution 1:100 of LMP2 and 1:50 of LMP7 antibodies (Abs) (Affinity- Biomol International, Plymouth Meeting, PA, USA). In addition, mouse monoclonal Ab to human 20S proteasome subunit alpha4 (diluted 1:25; Affinity- Biomol International, Plymouth Meeting, PA, USA) and rabbit polyclonal PA28alpha (diluted 1:50; Affinity- Biomol International, Plymouth Meeting, PA, USA) were used. Double stainings with Abs anti-LMP2 and anti-CD68 (Dako, Carpintera, CA, USA, diluted 1:150, clone KP1 that recognizes macrophages/microglial cells), anti LMP2 and anti-CD45RB (Dako, Carpintera, CA, USA, diluted 1:600; Abs from clones 2B11 + PD7\26 that recognizes antigens clustered as CD45RB specific for mature lymphocytes) were performed to identify microglia/macrophages or to distinguish between oligodendrocytes and lymphocytes. In addition, oligodendrocytes identification was also carried out by double immunostaining with anti-LMP2 and anti-Olig2 (Chemicon, Billerica, MA, USA; dilution 1:300; polyclonal rabbit that recognizes the transcription factor Olig2 [21] specific for oligodendrocytes) as well as anti-PA28-alpha and anti-Olig2. Double immunostainings with anti-LMP2 and anti-CD45RB or anti-CD68 were performed according to the following procedure: after biotinylated goat anti-polyvalent, two types of streptavidin were used, the first conjugated with peroxidase (Lab VISION Ultra vision Large Detection System Anti-polyvalent HRP, Fremont, CA, USA) and the second with alkaline phosphatase (DakoCytomation ChemMate Detectin Kit, Alkaline Phosphatase/RED, Rabbit/Mouse K5005, Carpintera, CA, USA) and two different chromogens: 3,3'-diaminobenzidine (Dako Liquid DAB-substrate- Chromogen system K3468, Carpintera, CA, USA) for streptavidin peroxidase and the fast red Working solution (CHROM) (Dako, Carpintera, CA, USA) for alkaline phosphatase. Double immunostainings with anti-LMP2/anti-Olig2 and with anti-PA28-alpha/anti-Olig2 were performed following the previous procedure but employing as second chromogen Perma\Blue AP Chromogen (Diagnostic Biosystems, Pleasonton, CA, USA) for alkaline phosphatase.
###end p 26
###begin title 27
Cell Cultures
###end title 27
###begin p 28
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto4">[22]</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Kuckelkorn1">[23]</xref>
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 187 192 <span type="species:ncbi:9606">human</span>
Lymphoblastoid cell lines (LcLs) are human B lymphocytes immortalized with Epstein Barr virus (EBV) which mainly express immunoproteasomes, as previously reported [22]. T2 cell line is a human T cell leukemia/B cell line hybrid defective in TAP1/TAP2 and LMP2/LMP7 subunits and expressing the HLA-A*0201 allele [23]. LcLs and T2 cell lines were cultured in RPMI1640 medium supplemented with 10% FCS.
###end p 28
###begin title 29
###xml 45 53 <span type="species:ncbi:9606">Patients</span>
Isolation of DNA from LcLs and Genotyping of Patients, Controls and LcLs
###end title 29
###begin p 30
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto4">[22]</xref>
###xml 392 396 392 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto3">[12]</xref>
DNA from LcLs was collected from 15*106 cells using TRIZOL reagent (Life Technologies, Paisley, UK) as previously reported [22]. DNA from donors for the genetic study was obtained from peripheral blood and genotyped for LMP2 codon 60 polymorphism, HLA-A*02 and HLA-DRB1*15 alleles. LMP2 genotyping was performed using standard PCR methods and DNA enzymatic digestions as previously described [12]. Genotyping for HLA-A*02 and HLA-DRB1*15 was performed by PCR-SSP analysis; as internal controls, regions of 330 bp of beta2 microglobulin and 520 bp of MOG (Myelin Oligodendrocyte Glycoprotein) promoter were amplified.
###end p 30
###begin title 31
20S Proteasome and PA28-alphabeta Purifications
###end title 31
###begin p 32
###xml 128 131 121 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto2">[8]</xref>
PA28-alphabeta and 20S proteasomes were purified from 9 LcLs (genotyped for LMP2 codon 60 polymorphism) as previously described [8]. The final step of the PA28-alphabeta purification was the fractioning by chromatography on a phenylsepharose column of pooled material obtained from all the LCLs. Isolated PA28-alphabeta stimulated proteasomal activity on Suc-LLVY-MCA substrate up to five-fold and no activity was observed in controls without 20S proteasome testifying the absence of protease contamination in the PA28-alphabeta preparation. Final purified PA28-alphabeta was tested on SDS-PAGE and stained with Comassie-Blue.
###end p 32
###begin title 33
Digestion of Long Substrates, Epitope Detection and Their Quantification by Mass Spectrometry
###end title 33
###begin p 34
###xml 42 49 42 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 214 221 207 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 248 255 237 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 600 607 555 562 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 634 641 585 592 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 849 853 785 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto4">[22]</xref>
###xml 1319 1326 1248 1255 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 1717 1724 1642 1649 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 1790 1791 1715 1716 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1879 1886 1804 1811 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 2143 2151 2061 2069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de facto</italic>
The digestion of the synthetic peptide MBP102-129 by purified 20S proteasomes+/-PA28-alphabeta was performed in Hepes buffer in different condition. In particular, to examine the effects of LMP2 polymorphism on MBP102-129 degradation, 20 microg MBP102-129 peptide was dissolved in 100 microl buffer-1 (20 mM Hepes pH 7.8, 2 mM MgAcetate, 1 mM dithiothreitol) and incubated with 0.5 microg 20S proteasome or dissolved in 100 microl buffer-2 (20 mM Hepes pH 7.8, 1 mM dithiothreitol) and incubated with 0.25 microg 20S proteasome+3 microl PA28-alphabeta. To examine the effects of PA28-alphabeta on MBP102-129 degradation, 20 microg MBP102-129 was incubated with 0.25 microg 20S proteasome+/-3 microl PA28-alphabeta. Digestions were stopped by acidic inactivation and samples frozen. Samples were analyzed by mass spectrometry as previously described [22]. Briefly, they were quantified by C18 reversed phase HPLC (HP1100, Agilent) followed by an ESI-MS analyses performed online with a LCQ ion trap mass spectrometer (Thermo Fisher). Peptides were identified by their molecular masses calculated from the m/z peaks of the single or multiple charged ions and were confirmed by tandem mass spectrometry sequencing analyses. To test the absence of protease contamination in the PA28-alphabeta preparation, the substrate MBP102-129 was digested in the usual digestion solution without 20S proteasomes for 60 mins and no detectable degradation of the substrate was observed. Moreover, when 20S proteasomes were inhibited by MG132 (final concentration of 5 microM) no substrate degradation was observed, confirming the absence of other proteases in the 20S proteasome preparation. The impact of LMP2 R60H polymorphism on MBP102-129 degradation was tested computing the degradation rate constant (K1) in a reaction of first order. The Specific Production (SP) of the fragments 10-18 (MBP111-119 epitope) by 20S immunoproteasomes +/- PA28-alphabeta carrying different LMP2 60 variants was computed as following: (fragment signal)/(signal of substrate degraded) multiplied for a factor of 1000 (to facilitate the comparison by readers). The SP provided de facto an estimation of the epitope produced per digested substrate based on the mass spectrometry signal. Only peptide signals in samples with similar substrate degradation and less than 50% of substrate consumption were compared to minimize errors during peptide quantification and the re-entry of products in the proteasome core, consequently obtaining epitope SP by 20S proteasomes carrying different LMP2 codon 60 variants at different percentage of substrate degraded (<25%, between 25% and 35%, between 35% and 50%).
###end p 34
###begin title 35
Flow Cytometric Analysis of the Binding Affinity of Epitopes-HLA-A*0201
###end title 35
###begin p 36
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 84 91 84 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 106 111 106 111 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">26&#8211;35</sub>
###xml 380 387 376 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s001">Fig. S1</xref>
T2 cells (3x105 cells/ml) were incubated with various concentrations of peptides MBP111-119 or (ELA)-MART126-35 (100-0,1 microg/ml) in serum-free RPMI 1640 medium for 16h. Afterwards, cells were washed and incubated with anti-HLA-A*02 Ab-FITC and the HLA-A*02 stabilization on cell surface by bound epitope was measured by flow cytometer FACScalibur. Net fluorescence reported in Fig. S1 was computed by subtraction of fluorescence detected in control samples (with Ab and without peptides).
###end p 36
###begin title 37
Statistical Analyses
###end title 37
###begin p 38
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 603 604 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 743 744 732 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 958 962 947 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Lewontin1">[24]</xref>
###xml 968 969 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 969 973 958 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Devlin1">[25]</xref>
###xml 1018 1022 1007 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Barrett1">[26]</xref>
Statistical analyses of in vitro digestion data were performed using the tests of Monte Carlo Anova to evaluate the effect of LMP2 R60H polymorphism, t-student for independent samples to evaluate the effect of LMP2 60H allele and Mann-Whitney test to evaluate the effect of PA28-alphabeta. To compare mass spectrometry values obtained from different experiments, mass spectrometry signals were standardized within each degradation set and then compared. In each data set, homogeneity of variance was checked by Levene's test. Comparisons of genetic distributions were assessed by Monte Carlo Pearson chi2 test. Investigation of MS onset age was performed with Monte Carlo Anova test. Hardy Weinberg equilibrium was tested using the Pearson chi2 test. p<0.05 was considered statistically significant. All the analyses were implemented using SPSS software. Pair-wise linkage disequilibrium was evaluated by two linkage disequilibrium parameters, Lewontin's D2 [24] and r2[25], which were both calculated in haploview () [26].
###end p 38
###begin title 39
Results
###end title 39
###begin title 40
###xml 55 63 <span type="species:ncbi:9606">Patients</span>
Immunoproteasome Subunits Are Present in the CNS of MS Patients (and Concentrated in MS Plaques) but Not of Young Controls
###end title 40
###begin p 41
###xml 490 497 476 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g001">Fig. 1A</xref>
###xml 539 546 525 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g001">Fig. 1B</xref>
###xml 717 727 699 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g001">Fig. 1C, D</xref>
###xml 914 924 896 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g001">Fig. 1E, F</xref>
###xml 947 957 925 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g001">Fig. 1G, H</xref>
###xml 1069 1080 1040 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g001">Fig. 1I &amp; L</xref>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
###xml 1059 1067 <span type="species:ncbi:9606">patients</span>
Although the mechanisms of MS are still largely unknown, some cell types seem to be involved in the pathogenesis of this disease. Therefore, we first investigated if immunoproteasome and PA28-alphabeta subunits are expressed in MS CNS and in which cells. Grey and white matters of parietal lobe from three MS patients and two young controls were initially stained with Abs specific for constitutive proteasome (beta1), immunoproteasome (LMP2 & LMP7) and PA28-alpha subunits. In the cortex (Fig. 1A) and in the plaques of the white matter (Fig. 1B) of MS patients, LMP2 was detected in different cell types. Similar results were obtained staining the same area with Abs anti-LMP7 (data not shown) and anti-PA28-alpha (Fig. 1C, D). In contrast, all stainings were negative both in cortex and white matter of the same CNS area of young controls except for luminal endothelial cells, which were positive to anti-LMP2 (Fig. 1E, F) and anti-PA28-alpha (Fig. 1G, H) Abs. As expected, proteasome beta1 and alpha4 subunits were expressed in all cell types, both in MS patients (Fig. 1I & L, respectively) and in young controls (data not shown).
###end p 41
###begin p 42
###xml 57 64 57 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g002">Fig. 2A</xref>
###xml 196 203 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g002">Fig. 2B</xref>
###xml 287 294 284 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g002">Fig. 2C</xref>
###xml 309 316 306 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g002">Fig. 2D</xref>
###xml 582 589 579 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g002">Fig. 2E</xref>
###xml 444 451 <span type="species:ncbi:9606">patient</span>
Moreover, LMP2 expression was predominant in MS plaques (Fig. 2A) compared to pre-plaque white matter and cortex while in the same CNS area of control only luminal endothelial cells were stained (Fig. 2B). Otherwise, beta1 subunit was equally distributed in grey and white matter of MS (Fig. 2C) and control (Fig. 2D). Such an accumulation of the immunoproteasome subunit in the plaque area was even more evident in the rostral medulla of a MS patient stained with Ab anti-LMP2, which mainly spotted the plaque into inferior olivar nucleus, whereas other areas were weakly stained (Fig. 2E).
###end p 42
###begin title 43
###xml 100 108 <span type="species:ncbi:9606">Patients</span>
Immunoproteasome and PA28-alphabeta Subunits Are Expressed in Different Cell Types in the CNS of MS Patients
###end title 43
###begin p 44
###xml 161 171 154 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g001">Fig. 1A, C</xref>
###xml 240 250 233 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g001">Fig. 1B, D</xref>
###xml 520 529 502 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g003">Figure 3A</xref>
###xml 1005 1012 987 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g003">Fig. 3B</xref>
###xml 1128 1135 1099 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g003">Fig. 3C</xref>
In the CNS areas affected by the disease, LMP2 and PA28-alphabeta were expressed in different cell types such as neurons, luminal endothelial cells, astrocytes (Fig. 1A, C) and, in white matter plaques, also in (putative) oligodendrocytes (Fig. 1B, D). To verify that oligodendrocytes express LMP2 & PA28-alphabeta and to distinguish them from lymphocytes, we performed a double IHC staining of MS parietal lobe slices using Abs anti-LMP2 (or anti-PA28-alpha) and anti-CD45RB (marker of mature lymphocytes). As shown in Figure 3A, lymphocytes present in white matter were positive to anti-LMP2 and anti-CD45RB staining. In addition, small rounded nuclei, positive to anti-LMP2 and negative to anti-CD45RB Abs, corresponding to oligodendrocytes, were present. This result was further confirmed by anti-LMP2 and anti-Olig2 labeling of the same MS brain area where oligodendrocytes were positive to both LMP2 and the oligodendrocytes transcription factor Olig2, while other cells were only stained for LMP2 (Fig. 3B). Similarly, PA28-alphabeta was detected in oligodendrocytes, positive to both anti-PA28-alpha and anti-Olig2 Abs (Fig. 3C).
###end p 44
###begin p 45
###xml 233 243 226 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g003">Fig. 3D, E</xref>
###xml 281 288 267 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g003">Fig. 3F</xref>
###xml 360 367 346 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 391 399 377 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 442 446 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Stohwasser1">[27]</xref>
Furthermore, we performed IHC double staining with Abs anti-CD68 (marker of microglial cells and macrophages) and anti-LMP2 (or anti-PA28-alphabeta) in MS parietal lobe. Microglial cells and macrophages expressed both CD68 and LMP2 (Fig. 3D, E) as well as CD68 and PA28-alphabeta (Fig. 3F), proving that immunoproteasomes were present in these cell types also in vivo and thus extending the in vitro observations of Stohwasser and co-workers [27].
###end p 45
###begin title 46
###xml 30 37 30 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
The Immunodominant Epitope MBP111-119 Is Produced In Vitro by Immunoproteasomes and PA28-alphabeta Increases the Efficiency of Its Production
###end title 46
###begin p 47
###xml 172 176 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Jurewicz1">[13]</xref>
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Tsuchida1">[14]</xref>
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Zang1">[15]</xref>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 198 205 198 205 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 304 311 304 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s001">Fig. S1</xref>
###xml 539 543 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Perchellet1">[28]</xref>
###xml 545 549 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Perchellet2">[29]</xref>
###xml 158 165 <span type="species:ncbi:9606">patient</span>
To test the involvement of immunoproteasome and its LMP2 R60H polymorphism in MS we investigated one of the major immunodominant self-epitopes detected in MS patient blood [13], [14], [15], i.e. MBP111-119 (HLA-A*0201-restricted). This epitope bound the MHC-I (HLA-A*0201) with a relative good affinity (Fig. S1) and is present in both the classic and golli MBP. This an important aspect because, as demonstrated in EAE, these two MBP families can play different roles in central and peripheral tolerance towards MBP-reactive CD8+ T cells [28], [29].
###end p 47
###begin p 48
###xml 22 29 22 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 62 69 62 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 84 92 84 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 265 269 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Strehl1">[30]</xref>
###xml 271 275 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-TextorisTaube1">[31]</xref>
The 28mer peptide (MBP102-129), which contains the epitope MBP111-119, was digested in vitro by 20S immunoproteasomes in presence or absence of PA28-alphabeta, which is strongly implicated in MHC-I antigen presentation by increasing the production of some epitopes [30], [31].
###end p 48
###begin p 49
###xml 78 85 78 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 87 94 87 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g004">Fig. 4A</xref>
###xml 114 121 114 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 282 289 282 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g004">Fig. 4B</xref>
We observed that this regulatory complex increased the degradation rate of MBP102-129 (Fig. 4A) as well as the MBP111-119 specific production (SP) (M-W U = 0; p = 0.002), as also indirectly confirmed by the concomitant higher SP of the flanking peptide 1-9 ( M-W U = 0; p = 0.002) (Fig. 4B).
###end p 49
###begin title 50
###xml 92 99 85 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
20S immunoproteasomes (+ PA28-alphabeta) carrying LMP2 60H allele have a lower SP of the MBP111-119 epitope.
###end title 50
###begin p 51
###xml 50 57 50 57 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 99 100 99 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
###xml 214 221 207 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 251 258 244 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 337 338 330 331 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
###xml 697 698 669 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 705 712 677 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 851 852 816 817 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</bold>
(A) Chart shows the time-dependent kinetics of MBP102-129 degradation increased in presence of PA28-alphabeta. (B) Specific production (SP) [expressed as: (peptide signal/consumed substrate signal)*1000] of the MBP111-119 epitope (peptide 10-18 of MBP102-129) and of the two flanking peptides 1-9 and 19-28 in absence or presence of PA28-alphabeta. The values are the average of the SPs measured at different time points. (C) In presence of PA28-alphabeta, H-carrier 20S immunoproteasomes have a significant lower epitope SP in all three selected ranges of substrate consumption. No significant difference emerged, on the contrary, in absence of PA28-alphabeta (D). (E) The similar rate constant K1 of MBP102-129 digestion by 20S immunoproteasomes (in presence of PA28-alphabeta) carrying the three LMP2 codon 60 variants. All values are given as mean+S.E.M. Statistical significance (p<0.05) is marked with *.
###end p 51
###begin title 52
###xml 55 62 55 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
LMP2 R60H Polymorphism Influences the Efficiency of MBP111-119 Production by 20S Immunoproteasomes in the Presence of PA28-alphabeta
###end title 52
###begin p 53
###xml 92 99 92 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 114 122 114 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 154 161 154 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 542 549 528 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g004">Fig. 4C</xref>
###xml 876 880 855 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g.</italic>
###xml 1127 1134 1106 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g004">Fig. 4D</xref>
To investigate the impact of the LMP2 R60H polymorphism on the production of the epitope MBP111-119, we performed in vitro digestions of the substrate MBP102-129 by 20S immunoproteasomes (with or without PA28-alphabeta) purified from 9 LcLs carrying different LMP2 R60H variants. The epitope SP in the presence of PA28-alphabeta was associated with the LMP2 R60H polymorphism (F = 15.49; p = 0.004) and was significantly lower (a decrease of 28.8%) in LMP2 H-carriers (t = 8.08; p<0.001) when less than the 25% of the substrate was consumed (Fig. 4C). Such a result was confirmed by a decreased epitope SP of 28.5% and 21.72% when 25-35% (t = 2.97; p = 0.021) or 35-50% (t = 4.75; p = 0.002) of substrate was consumed, respectively. Such an association of the LMP2 R60H polymorphism with the epitope SP was not detected in the absence of PA28-alphabeta (F = 0.306; p = 0.747, e.g., with 25-35% substrate consumed) and, accordingly, it was similar between LMP2 H-carriers and H-not-carriers when less than 25% (t = -0.47; p = 0.962), 25-35% (t = -0.77; p = 0.462) and 35-50% (t = 0.35; p = 0.744) of the substrate was consumed (Fig. 4D).
###end p 53
###begin p 54
###xml 85 92 85 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">102&#8211;129</sub>
###xml 132 136 132 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto4">[22]</xref>
###xml 244 245 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 247 254 236 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g004">Fig. 4E</xref>
Although LMP2 polymorphism influenced the epitope SP, it did not impinge upon the MBP102-129 degradation rate either in the absence [22] or in the presence of PA28-alphabeta as described by the comparison of the degradation rate constants Kappa1 (Fig. 4E) (F = 0.206; p = 0.820).
###end p 54
###begin title 55
LMP2 60HH Variant Decreases the Risk to Develop MS in HLA-A*02+ Female Population
###end title 55
###begin p 56
###xml 3 11 3 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 107 114 107 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111-119</sub>
###xml 433 440 433 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111-119</sub>
###xml 720 728 720 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s002">Table S1</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>
###xml 843 850 843 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009287-t001">Table 1</xref>
###xml 959 963 959 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g.</italic>
###xml 1035 1042 1035 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009287-t002">Table 2</xref>
###xml 1091 1098 1091 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009287-t003">Table 3</xref>
###xml 1278 1279 1278 1279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1332 1333 1332 1333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1753 1756 1753 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Fugger1">[3]</xref>
###xml 1758 1762 1758 1762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Bergamaschi1">[32]</xref>
###xml 1764 1768 1764 1768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Brynedal1">[33]</xref>
###xml 1770 1774 1770 1774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-DAlfonso1">[34]</xref>
###xml 1776 1780 1776 1780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Pastorino1">[35]</xref>
###xml 1885 1892 1885 1892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009287-t004">Table 4</xref>
###xml 1951 1958 1951 1958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009287-t005">Table 5</xref>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
###xml 492 500 <span type="species:ncbi:9606">patients</span>
###xml 636 644 <span type="species:ncbi:9606">patients</span>
###xml 793 801 <span type="species:ncbi:9606">patients</span>
###xml 920 928 <span type="species:ncbi:9606">patients</span>
###xml 1081 1089 <span type="species:ncbi:9606">patients</span>
###xml 1144 1152 <span type="species:ncbi:9606">patients</span>
As in vitro experiments showed that LMP2 60H allele decreases the production of the HLA-A*02-restricted MBP111-119 epitope we performed a genetic population study to test its possible impact on MS onset. We genotyped two independent samples of 694 and 598 MS patients as well as 845 geographically- and age-matched controls for LMP2 R60H, HLA-A*02 and HLA-DRB1*15 alleles, considering their gender. The impact of an alteration of MBP111-119 production on MS pathogenesis should be evident in patients able to present such an epitope on HLA-A*02 MHC-I variant. Accordingly, we compared the LMP2 R60H distribution in HLA-A*02 positive MS patients and control subjects. Both MS population showed the same genetic behavior (Table S1 & S2), hence we grouped them in a MS Italian population of 1262 patients and compared them to the control sample (Table 1). A significant decrease in LMP2 60HH frequency emerged in female MS patients carrying the HLA-A*02 allele (e.g. LMP2 60HH vs RR: p  =  0.005; OR  =  0.443; 95% CI  =  0.249 - 0.790) (Table 2) but not in HLA-A*02-positive male MS patients (Table 3) nor in HLA-A*02-negative female and male MS patients (data not shown). In female controls LMP2 60H was not in linkage disequilibrium (LD) neither with HLA-DRB1*15 (D'  =  0.02; r2 < 0.001; p > 0.05) nor with HLA-A*02 (D'  =  0.03; r2  =  0.001; p > 0.05). Both MS and control populations were in Hardy-Weinberg equilibrium for LMP2 codon 60 polymorphism (data not shown). Furthermore, HLA-A*02 allele was a protective factor against MS (p  =  0.001; OR  =  0.671; 95% CI  =  0.529 - 0.851) while HLA-DRB1*15 allele was a risk factor (p < 0.001; OR  =  2.525; 95% CI  =  1.801 - 3.754) (data not shown), as already reported in the Italian population too [3], [32], [33], [34], [35]. No effects on the MS onset age exerted by LMP2 polymorphism in HLA-A*02-positive female MS population (Table 4) and by HLA-A*02 in the total MS population was observed (Table 5).
###end p 56
###begin title 57
###xml 264 273 264 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s002">Tables S1</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>
Gender distribution in Italian MS and control populations. Values in brackets in distribution column are percentages. The Italian MS population described in this table is the result of sum of two independent Italian MS samples reciprocally in accordance (see also Tables S1 & S2).
###end title 57
###begin title 58
###xml 362 371 362 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s002">Tables S1</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>
LMP2 60HH variant decreases the risk to develop MS in HLA-A*02 carrier female population. Values in brackets in distribution column are percentages. Statistical results are reported for each genetic analysis. The Italian MS female population described in this table is the result of sum of two independent Italian MS samples reciprocally in accordance (see also Tables S1 & S2).
###end title 58
###begin title 59
###xml 346 355 346 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s002">Tables S1</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>
LMP2 R60H distribution in HLA-A*02 carrier MS and control male populations. Values in brackets in distribution column are percentages. Statistical results are reported for each genetic analysis. The Italian MS male population described in this table is the result of sum of two independent Italian MS samples reciprocally in accordance (see also Tables S1 & S2).
###end title 59
###begin title 60
###xml 301 310 301 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s002">Tables S1</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>
LMP2 R60H polymorphism and MS onset age in HLA-A*02 carrier female MS population. Means and standard deviations (SD) are reported. The Italian HLA-A*02 carrier female MS population described in this table is the result of sum of two independent Italian MS samples reciprocally in accordance (see also Tables S1 & S2).
###end title 60
###begin title 61
###xml 260 269 260 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s002">Tables S1</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>
MS onset age in HLA-A*02 carrier and not-carrier MS populations. Means and standard deviations (SD) are reported. The Italian MS population described in this table is the result of sum of two independent Italian MS samples reciprocally in accordance (see also Tables S1 & S2).
###end title 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 220 224 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-ElEtr1">[36]</xref>
###xml 226 230 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Pelfrey1">[37]</xref>
###xml 232 236 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Moldovan1">[38]</xref>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 355 358 355 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Kramer1">[9]</xref>
###xml 682 686 682 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Moldovan1">[38]</xref>
###xml 1093 1100 1093 1100 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 1568 1572 1568 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 1669 1673 1662 1666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Liu1">[39]</xref>
###xml 1688 1692 1681 1685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Papenfuss1">[40]</xref>
###xml 1765 1771 1751 1757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g003">Fig. 3</xref>
###xml 1871 1875 1857 1861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g.</italic>
###xml 1879 1886 1865 1872 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 2038 2044 2024 2030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g003">Fig. 3</xref>
###xml 2226 2229 2212 2215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Friese1">[1]</xref>
###xml 2324 2330 2303 2309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009287-g001">Fig. 1</xref>
###xml 2381 2385 2360 2364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Bourdoulous1">[41]</xref>
###xml 2387 2391 2366 2370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Risau1">[42]</xref>
###xml 2393 2397 2372 2376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Wilcox1">[43]</xref>
###xml 2463 2467 2442 2446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g.</italic>
###xml 2471 2478 2450 2457 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 2695 2699 2674 2678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Galea1">[44]</xref>
###xml 3175 3179 3154 3158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g.</italic>
###xml 3220 3223 3199 3202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Friese1">[1]</xref>
###xml 3319 3323 3291 3295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Macagno1">[45]</xref>
###xml 3472 3476 3444 3448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Perchellet1">[28]</xref>
###xml 3478 3482 3450 3454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Perchellet2">[29]</xref>
###xml 3545 3549 3517 3521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e.g.</italic>
###xml 3553 3560 3525 3532 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
The observed gender-dependency of the genetic association is consistent with other studies describing a gender dimorphism in cytokine response towards myelin antigens and a hormonal regulation of the immune system in MS [36], [37], [38]. LMP2 R60H polymorphism association is gender- (male-) dependent in another autoimmune disease, i.e. dermal psoriasis [9]. The bulk of these indirect observations suggest a connection between LMP2 codon 60 polymorphism, immunoproteasome activity and gender in immunological dysfunctions. Despite the scarcity of experimental evidences we might speculate that the cytokines responses towards MHC-I myelin epitopes (as demonstrated for the MHC-II [38]) is altered by gender, generating a scenario in which the influence of the LMP2 R60H polymorphism on specific myelin epitopes might impinges upon the MS onset only in females. Indeed, the decreased risk of female subjects carrying the HLA-A*02 allele and the LMP2 60HH variant to develop MS might be explained by the impact of the LMP2 polymorphism on the generation of the HLA-A*02-restricted epitope (MBP111-119) as well of other epitopes not investigated in this study. Indeed, the decreased presentation of this epitope on the MHC-I (HLA-A*02) complex of antigen presenting cells or other cells involved in MS pathways could reduce the probability to disrupt the physiological tolerance (central or peripheral) of MBP-reactive CD8+ T cells and/or their cytotoxicity towards oligodendrocytes thereby restraining the MS onset. We showed that the main producers of myelin sheets, i.e. the oligodendrocytes, as well as the macrophages/microglial cells, which express PA28-alphabeta [39] and golli MBP [40] during EAE, are positive to LMP2 and PA28-alphabeta staining in MS CNS (Fig. 3). In oligodendrocytes, a decreased presentation mediated by the LMP2 60HH variant of MBP epitopes (e.g. MBP111-119) on HLA-A*02 MHC could attenuate the cytotoxic activity of MBP-reactive CD8+ T cells against their main cell targets. In macrophages/microglial cells (Fig. 3), the lower presentation of these epitopes could restrain a further clonal expansion of self-reactive CD8+ T cells, which has been assumed as one of the key steps of MS development [1]. Taking into account that CNS endothelial cells express immunoproteasomes and PA28-alphabeta (Fig. 1) as well as they can present MBP in animal models [41], [42], [43], the LMP2 60HH-dependent altered expression of the MBP epitopes (e.g. MBP111-119) might also affect the blood-brain barrier (BBB) crossing. Indeed, it has been recently proposed that, after priming, activated CD8+ T cells cross the BBB by an antigen-specific interaction with cerebral endothelium [44]. Thus, endothelial cells carrying HLA-A*02 and LMP2 60HH might lead to a decreased BBB crossing by MBP-reactive CD8+ T cells during the early phases of neuroinflammation, affecting MS development. Furthermore, LMP2 R60H polymorphism might influence not only the mechanisms leading to MS that occur in CNS but also the complex balance between central and peripheral tolerance of MBP-restricted CD8+ T cells and thereby their pathological activation in peripheral lymph nodes (e.g. cervical and lumbal) by dendritic cells [1]. Indeed, these cells, which express immunoproteasomes and PA28-alphabeta at their mature stage [45], play a key role in the thymic selection and in peripheral activation of MBP-restricted CD8+ T cells by the presentation of endogenous MBP on MHC-I [28], [29]. As consequence, an alteration of the amount of MBP epitopes (e.g. MBP111-119) presented on dendritic cells due to the LMP2 polymorphism might affect the repertoire of MBP-reactive CD8+ T cells and, thereby their eventual activation during the early phases of MS onset.
###end p 63
###begin p 64
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Bergamaschi1">[32]</xref>
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Brynedal1">[33]</xref>
###xml 233 237 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Silva1">[46]</xref>
###xml 476 479 476 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Friese2">[4]</xref>
###xml 667 675 667 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 697 704 697 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 983 987 983 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Tsuchida1">[14]</xref>
###xml 1007 1014 1007 1014 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 1360 1364 1352 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Jurewicz1">[13]</xref>
###xml 1366 1370 1358 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Zang1">[15]</xref>
###xml 1075 1083 <span type="species:ncbi:9606">patients</span>
Our investigation also addresses the complex role that HLA-A*02 appears to have in MS. We observed a decreased risk to develop MS in Italian female population carrying the HLA-A*02 allele, in agreement with other studies [32], [33], [46]. Although the mechanisms are still unknown, HLA-A*02 variant in a specific EAE model appeared to increase the negative selection of MBP-reactive CD8+ thymocytes and to decrease the responsiveness of MBP-reactive CD8+ T cells in periphery [4], thereby protecting from EAE. Our results suggest that LMP2 60HH variant impinges upon the likelihood to develop MS but only in HLA-A*02 carriers. Likewise, LMP2 60H allele decreases the in vitro generation of the MBP111-119 epitope by immunoproteasomes thereby suggesting that this specific myelin epitope could play a pathogenetic role in MS when presented on HLA-A*02 MHC. Accordingly, several CD8+ T cells reactive to HLA-A*02 myelin epitopes have been identified in peripheral blood of MS subjects [14]. In particular, MBP111-119-reactive CD8+ T cells, which are increased three fold in MS patients peripheral blood, are CD45RO+ memory T cells secreting TNF-alpha and IFN-gamma after epitope challenging and are cytotoxic towards antigen presenting cells and oligodendrocytes, thus supporting the postulate that these CD8+ T cells could contribute to the tissue injury in MS [13], [15].
###end p 64
###begin p 65
###xml 206 209 206 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-DiazHernandez1">[6]</xref>
###xml 211 214 211 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto1">[7]</xref>
###xml 216 220 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto5">[47]</xref>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Meuth1">[48]</xref>
###xml 328 332 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Mishto6">[49]</xref>
###xml 334 338 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Wehenkel1">[50]</xref>
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Muchamuel1">[51]</xref>
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009287-Kuhn1">[52]</xref>
In conclusion, our data suggests that the presence of immunoproteasomes in the CNS could be a marker of a pathological scenario involving neuroinflammation (autoimmunity, neurodegeneration but also ageing) [6], [7], [47], therefore putting immunoproteasome forward as potential candidate for future therapeutic approaches [48], [49], [50], [51], [52].
###end p 65
###begin title 66
Supporting Information
###end title 66
###begin p 67
###xml 3 10 3 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 218 225 214 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 240 245 236 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">26&#8211;35</sub>
###xml 401 408 397 404 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111&#8211;119</sub>
###xml 450 455 446 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">26&#8211;35</sub>
MBP111-119 binds the HLA-A*0201 complex with relative good affinity. A) Comparison of the amount of HLA-A*0201 complexes (marked with a FITC-Ab) presented on the outer surface of T2 cells treated with 100 microg/ml MBP111-119 or (ELA)-MART126-35 epitopes. In particular, signals of T2 cells are reported: i. without FITC-Ab and epitope; ii. without epitopes and with FITC-Ab; iii. with FITC-Ab and MBP111-119 epitope; iv. with FITC-Ab and (ELA)-MART126-35 epitope. B) The chart shows the binding affinity of the peptides for the MHC class I complexes presented to the outer surface of T2 cells. The net fluorescence is the fluorescence's difference between the cells incubated with and without the epitopes.
###end p 67
###begin p 68
(2.00 MB TIF)
###end p 68
###begin p 69
Click here for additional data file.
###end p 69
###begin p 70
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
LMP2 60HH, HLA-A*02 and gender frequency in the first investigated Italian MS population (n = 694) compared to age-matched Italian control population (n = 845). (A) Gender distribution in MS patients and control populations. (B) LMP2 R60H polymorphism and allele distribution in MS and control HLA-A*02 carrier populations, taking into account the gender. (C) LMP2 R60H polymorphism and MS onset age in HLA-A*02-positive female MS patients. Values in brackets in distribution column are percentages. Statistical results are reported for each genetic analysis.
###end p 70
###begin p 71
(0.14 MB DOC)
###end p 71
###begin p 72
Click here for additional data file.
###end p 72
###begin p 73
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 432 440 <span type="species:ncbi:9606">patients</span>
LMP2 60HH, HLA-A*02 and gender frequency in the second investigated Italian MS population (n = 598) compared to age-matched Italian control population (n = 845). (A) Gender distribution in MS patients and control populations. (B) LMP2 R60H polymorphism and allele distribution in MS and control HLA-A*02 carrier populations, taking into account the gender. (C) LMP2 R60H polymorphism and MS onset age in HLA-A*02-positive female MS patients. Values in brackets in distribution column are percentages. Statistical results are reported for each genetic analysis.
###end p 73
###begin p 74
(0.14 MB DOC)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
We would like to thank Dr. Ulrike Kuckelkorn and Dr. Frederic Ebstein for supervision of proteasome purification and binding affinity assay, Prof. Annalisa Pession to have supervised the IHC experiments, Dr. Daniel Remondini for the statistical analysis support, Dr. Fabiola Olivieri for the logistic support, Paola Rosini and Laura Bergamaschi for genotyping, Donovan Payne and Roisin O'Connor for the linguistic revision of the manuscript.
###end p 76
###begin title 77
References
###end title 77
###begin article-title 78
Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?
###end article-title 78
###begin article-title 79
Multiple sclerosis: the environment and causation.
###end article-title 79
###begin article-title 80
From genes to function: the next challenge to understanding multiple sclerosis.
###end article-title 80
###begin article-title 81
Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis.
###end article-title 81
###begin article-title 82
Antigen processing by the proteasome.
###end article-title 82
###begin article-title 83
Neuronal induction of the immunoproteasome in Huntington's disease.
###end article-title 83
###begin article-title 84
Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains.
###end article-title 84
###begin article-title 85
Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics.
###end article-title 85
###begin article-title 86
Strong associations of psoriasis with antigen processing LMP and transport genes TAP differ by gender and phenotype.
###end article-title 86
###begin article-title 87
###xml 107 115 <span type="species:ncbi:9606">patients</span>
LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis.
###end article-title 87
###begin article-title 88
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis.
###end article-title 88
###begin article-title 89
###xml 75 80 <span type="species:ncbi:9606">human</span>
Age dependent impact of LMP polymorphisms on TNFalpha-induced apoptosis in human peripheral blood mononuclear cells.
###end article-title 89
###begin article-title 90
###xml 32 37 <span type="species:ncbi:9606">human</span>
MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes.
###end article-title 90
###begin article-title 91
###xml 38 43 <span type="species:ncbi:9606">human</span>
Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides.
###end article-title 91
###begin article-title 92
Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis.
###end article-title 92
###begin article-title 93
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
###end article-title 93
###begin article-title 94
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
###end article-title 94
###begin article-title 95
Intermediate-type 20 S proteasomes in HeLa cells: "asymmetric" subunit composition, diversity and adaptation.
###end article-title 95
###begin article-title 96
Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.
###end article-title 96
###begin article-title 97
The relation between inflammation and neurodegeneration in multiple sclerosis brains.
###end article-title 97
###begin article-title 98
Spiking and nonspiking classes of oligodendrocyte precursor glia in CNS white matter.
###end article-title 98
###begin article-title 99
A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms.
###end article-title 99
###begin article-title 100
Incorporation of major histocompatibility complex-encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma.
###end article-title 100
###begin article-title 101
A general asymptotic property of two-locus selection models.
###end article-title 101
###begin article-title 102
A comparison of linkage disequilibrium measures for fine-scale mapping.
###end article-title 102
###begin article-title 103
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 103
###begin article-title 104
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
Biochemical analysis of proteasomes from mouse microglia: induction of immunoproteasomes by interferon-gamma and lipopolysaccharide.
###end article-title 104
###begin article-title 105
Crosspresentation by nonhematopoietic and direct presentation by hematopoietic cells induce central tolerance to myelin basic protein.
###end article-title 105
###begin article-title 106
CD8+ T cells maintain tolerance to myelin basic protein by 'epitope theft'.
###end article-title 106
###begin article-title 107
Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing.
###end article-title 107
###begin article-title 108
The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation.
###end article-title 108
###begin article-title 109
HLA-class I markers and multiple sclerosis susceptibility in the Italian population.
###end article-title 109
###begin article-title 110
HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis.
###end article-title 110
###begin article-title 111
A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy.
###end article-title 111
###begin article-title 112
Association between protective and deleterious HLA alleles with multiple sclerosis in Central East Sardinia.
###end article-title 112
###begin article-title 113
Steroid hormones in multiple sclerosis.
###end article-title 113
###begin article-title 114
Effects of sex hormones on costimulatory molecule expression in multiple sclerosis.
###end article-title 114
###begin article-title 115
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Multiple sclerosis patients show sexual dimorphism in cytokine responses to myelin antigens.
###end article-title 115
###begin article-title 116
Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord.
###end article-title 116
###begin article-title 117
Induction of Golli-MBP expression in CNS macrophages during acute LPS-induced CNS inflammation and experimental autoimmune encephalomyelitis (EAE).
###end article-title 117
###begin article-title 118
Anergy induction in encephalitogenic T cells by brain microvessel endothelial cells is inhibited by interleukin-1.
###end article-title 118
###begin article-title 119
###xml 98 101 <span type="species:ncbi:10116">rat</span>
Immune function of the blood-brain barrier: incomplete presentation of protein (auto-)antigens by rat brain microvascular endothelium in vitro.
###end article-title 119
###begin article-title 120
###xml 47 57 <span type="species:ncbi:10141">guinea-pig</span>
Presentation of myelin basic protein by normal guinea-pig brain endothelial cells and its relevance to experimental allergic encephalomyelitis.
###end article-title 120
###begin article-title 121
An antigen-specific pathway for CD8 T cells across the blood-brain barrier.
###end article-title 121
###begin article-title 122
Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation.
###end article-title 122
###begin article-title 123
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Protective role of the HLA-A*02 allele in Portuguese patients with multiple sclerosis.
###end article-title 123
###begin article-title 124
Immunoproteasomes and immunosenescence.
###end article-title 124
###begin article-title 125
Recent clinical trials and future therapies.
###end article-title 125
###begin article-title 126
Role of immunoproteasome in ageing and neurodegenerative diseases.
###end article-title 126
###begin article-title 127
###xml 74 79 <span type="species:ncbi:9606">human</span>
Proteasome modulators: essential chemical genetic tools for understanding human diseases.
###end article-title 127
###begin article-title 128
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.
###end article-title 128
###begin article-title 129
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
###end article-title 129
###begin p 130
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 130
###begin p 131
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was financed in part by the grant Giovani Ricercatori 2007 from Italian Ministry of Health to MM, DG and FMB, by a grant from the European Commission Integrated Project PROTEOMAGE (FP6) to CF, by the finalized projects of Fondazione Italiana Sclerosi Multipla (FISM) cod. 2003/R26 and BioPharmaNet to CF and 2002/R/40 and 2005/R/10, 2008/R/11 (Genoa) to SD'A, by the University of Bologna (FRO) to MPF, by the Regione Piemonte (Ricerca Sanitaria Finalizzata Project and Ricerca Sanitaria Applicata-CIPE Project) to SD'A, by Associazione Amici del Centro Dino Ferrari and IRCCS Ospedale Maggiore Policlinico, Milano to DG and by the grants Sonderforschungsbereich (SFB-507, SFB-421) to PMK and US, the grants TR43 and Neurocure to PMK. MM benefited from the A.V. Humboldt PostDoc fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 131

